Drug Therapy and Interactions in Pediatric Oncology (eBook)

Carolina Witchmichen Penteado Schmidt: Oncology Pharmacist with extensive experience with Pediatric Oncohematology and Chemotherapy in Children. Oncological Hospital Pharmacy Specialist; Planning and Business Management Specialist. Extensive experience in hospitals and clinics, with Pharmacy, Drug Interactions, Pediatrics, Oncology, Hematology, Neonatology, Intensive Health Care and Infectology. Academic experience in the following fields: Pharmacy, Pediatrics, Oncology and Hematology.Fabiana Gatti de Menezes: Graduated in Pharmacy and Biochemistry, University of São Paulo, Brazil. Master in Pharmacology, Faculty of Medical Sciences, State University of Campinas, Brazil; PhD in Pharmacology, Institute of Biomedical Sciences of University of São Paulo, Brazil; Specialization in Clinical Pharmacy at Hospital Israelita Albert Einstein, Brazil. Professor and researcher in the following areas: Clinical Pharmacy, Pharmacoepidemiology and Pharmaceutical Care. Professor of Pharmacotherapy, Clinical Research Pharmacy and Clinical Pharmacy at postgraduate courses: Hospital Pharmacy (Oswaldo Cruz College, Brazil); Hospital and Clinical Pharmacology (Gama Filho University, Brazil); Oncological Hospital Pharmacy (AC Camargo Cancer Center, Brazil). Experience in Clinical Pharmacy: Pharmaceutical Care, Pharmacoepidemiology, Pharmacovigilance, Pharmacoeconomics, Hospital Pharmacy, Drug Interactions, and Industry. 

1. Introduction.- 2. The Main Diseases In Pediatric Oncohematology2.1. Hodgkin Lymphoma2.2. Chronic Myeloid Leukemia (CML)2.3. Acute Myeloid Leukemia (AML)2.4. Acute Lymphoblastic Leukemia (ALL)2.5. Osteosarcoma2.6. Central Nervous System Tumors.- 3. The Main Protocols In Pediatric Oncohematology3.1. Hodgkin Lymphoma3.2. Chronic Myeloid Leukemia (CML)3.3. Hematologic Control with Hydroxyurea3.4. Acute Myeloid Leukemia (AML)3.5. Acute Myeloid Leukemia - Berlin-Frankfurt-Münster Treatment (BFM2004) – adapted from HEMORIO3.6. Acute Myeloid Leukemia - Berlin-Frankfurt-Münster Treatment (BFM95)3.7. Brain Tumors3.8. High Dose Protocol – HD-CAV (Neuroblastoma)3.9. COPE/Baby Brain I3.10. 8 in 1 Chemotherapy3.11. CAV-P/VP (Neuroblastoma)3.12. Wilms Tumor3.13. AVD3.14. AV (Wilms Tumor Stage IV and Favorable Histology)3.15. Advanced Burkkit Lymphoma and ALL L33.16. Burkkit Lymphoma Protocol LMB893.17. Retinoblastoma3.18. Non-Hodgkin Lymphoma3.19. CODOX-M3.20. Osteosarcoma3.21. HD MTX3.22. ICE3.23. Hepatoblastoma.- 4. Background On Drug Interactions4.1. General Concepts4.2. Pharmacokinetic Interactions4.3. Pharmacodynamic Interactions4.4. Beneficial Drug Interactions of Clinical Protocols4.5. Methotrexate with Leocovorin4.6. Doxorubicin with Dexrazoxane4.7. Mesna with Ifosfamide or with Cyclophosphamide4.8. Methotrexate with Sodium Bicarbonate4.9. Drug-drug Interactions4.10. Pharmacokinetic Drug Interactions with CYP4504.11. Pharmacokinetic Drug Interactions with CYP450: Anticonvulsant4.12. Pharmacokinetic Drug Interactions Involving Binding Proteins and Plasmatic Proteins Affinity4.13. α1- Acid Glycoprotein4.14. Albumin4.15. Pharmacokinetic Drug Interactions Involving Transport Proteins4.16. P Glycoprotein4.17. ATP Binding Cassettes4.18. Drug Interactions Involving Prodrugs4.19. Drug Interactions between Methotrexate and Nonsteroidal Anti-inflammatory Drugs4.20. 6-Mercaptopurin and Allopurinol4.21. Antineoplasics and Antiemetics4.22. Aprepitant4.23. Dexamethasone with Antineoplasics4.24. Antacids with Antineoplasics4.25. Antimicrobial Drugs with Antineoplasics4.26. Macrolides Antimicrobial4.27. Aminoglicosydes Antimicrobial4.28. Tuberculosis Antimicrobial Drugs4.29. Ceftriaxhone and Platinum Composers4.30. Penicilamic Antibiotical Drug and Antineoplasics4.31. Sulfamethoxazole withTrimethoprim and Methotrexate4.32. Antineoplasics and Antifungics4.33. Amphotericin B4.34. Azolic Antifungics4.35. Anticonvulsant and Antineoplasics.- 5. Food - Drug Interactions.- 6. Body Surface.- 7. Carboplatin Dosage Calculation.- 8. Creatinine Clearance Estimate